Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: A claims database study

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1255-1262

  Hatoum, Hind T ^a,c   Lin, Swu Jane ^a   Buchner, Deborah ^b   Kim, Edward ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b EISAI INC   (United States)

^c Eisai Inc ^*  (United States)

Author keywords

Azacitidine (AZA); Decitabine (DAC); Hypomethylating agents (HMAs); Myelodysplastic syndrome (MDS); Supportive care (SC); Transfusion dependence

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIANEMIC AGENT; AZACITIDINE;

AGED; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; FOLLOW UP; GENDER; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATIENT CARE; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SAMPLE SIZE; THROMBOCYTE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 79956067786     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.576236     Document Type: Article

References (25)

1. National Cancer Institute (NCI): US Institutes of Health. Myelodysplastic Syndromes Treatment (PDQ) General Information about Myelodysplastic Syndromes. Available at: http://www.cancer.gov/cancertopics/pdq/treat-ment/myelodysplastic/ . Accessed May 15, 2010
2. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-60 (Pubitemid 29249435)
3. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52
4. Ma X, Does M, Raza A, Mayne AT. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:1536-42 (Pubitemid 46595689)
5. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8
6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. V.2.2010. available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp [Last accessed 15 May 2010]
7. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263-8 (Pubitemid 39331821)
8. Hoffmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005;56:1-16 (Pubitemid 40299770)
9. Lawrence LW. Refractory anemia and the myelodysplastic syndromes. Clin Lab Sci 2004;17:178-86
10. Gupta P, LeRoy SC, Luikart SD, et al. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. LeukRes 1999;23:953-9 (Pubitemid 29460832)
11. Ria R, Moschetta M, Reale A, et al. Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 2009;4:413-23
12. Frytak J, Henk HJ, de Castro CM, et al. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin 2009;25:1941-51
13. Szende A, Schaefer C, Goss TF, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes 2009;7:81
14. Sekeres MA, Schoonen M, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-51
15. Greenberg PL, Cosier LE, Ferro SA, et al. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Natl Compr Cane Netw 2008;6:942-53
16. Greenberg P. Use of ESAs to treat patients with myelodysplastic syndromes. Hematology 2010;7:1-16
17. ; NY: Eisai Inc., 2006
18. Vidaza (azacitidine for injectable suspension) [prescribing information] Summit, NJ: Celegene Corp, 2008
19. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-40 (Pubitemid 34525728)
20. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803
21. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83 (Pubitemid 17055592)
22. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23: 7594-603 (Pubitemid 46291823)
23. Weinman S, Marshall D, AuBuchon J, et al. Survival after transfusion as assessed in a large multistate US cohort. Transfusion 2004;44:386-90 (Pubitemid 38365515)
24. Pan F, Peng S, Fleurence R, et al. Economic analysis of decitabine versus best supportive care in the treatment of intermediate and high risk myelodysplastic syndromes (MDS) from a US payer perspective. Clin Ther 2010; 32:2444-50
25. Edlin R, Connock M, Tubeuf S, et al. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technol Assess 2010;14(Suppl 1):69-74